AWM
TOVX icon

Axxcess Wealth Management’s Theriva Biologics TOVX Stock Holding History

Axxcess Wealth Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40
Closed -$3K – 664
2022
Q1 		$3K Buy
+40
New +$2.73K ﹤0.01% 626

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Axxcess Wealth Management's TOVX Position: Q2 2022 in Review

Axxcess Wealth Management sold out of Theriva Biologics (TOVX) in Q2 2022, closing a stake of 40 shares — an estimated $3K sold.

Axxcess Wealth Management first reported a position in TOVX in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 30 funds tracked by Wall St. Rank hold TOVX as of Q2 2022.

  • Axxcess Wealth Management reported no remaining Theriva Biologics position as of Q2 2022 after selling out during the quarter.
  • Axxcess Wealth Management sold 40 Theriva Biologics shares in Q2 2022, an estimated $3K.
  • Axxcess Wealth Management first reported a position in Theriva Biologics in Q1 2022 and held it in 1 quarter.
  • Axxcess Wealth Management's Theriva Biologics position peaked at $3K in Q1 2022.
  • 30 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2022.

Based on Axxcess Wealth Management's 13F filing for Q2 2022, filed 11 Aug 2022.